Entry Name Platinum drug resistance - Macaca mulatta (rhesus monkey)
Description Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.
Class Human Diseases; Drug resistance: antineoplasticBRITE hierarchy
Pathway map Ortholog table Organism Macaca mulatta (rhesus monkey) [GN:
mcc ]
Reference Authors Siddik ZH
Title Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Journal Reference Authors Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Buges C, Bystrup S, Esteller M, Abad A
Title Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Journal Reference Authors Kelland L
Title The resurgence of platinum-based cancer chemotherapy.
Journal Reference Authors Dilruba S, Kalayda GV
Title Platinum-based drugs: past, present and future.
Journal Reference Authors Lu HP, Chao CC
Title Cancer cells acquire resistance to anticancer drugs: an update.
Journal Reference Authors Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S
Title Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
Journal Reference Authors Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G
Title Molecular mechanisms of cisplatin resistance.
Journal Reference Authors Stewart DJ
Title Mechanisms of resistance to cisplatin and carboplatin.
Journal Reference Authors Koberle B, Tomicic MT, Usanova S, Kaina B
Title Cisplatin resistance: preclinical findings and clinical implications.
Journal Reference Authors Jacobsen C, Honecker F
Title Cisplatin resistance in germ cell tumours: models and mechanisms.
Journal Reference Authors Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK
Title Chemoresistance in human ovarian cancer: the role of apoptotic regulators.
Journal Reference Authors Sousa GF, Wlodarczyk SR, Monteiro G.
Title Carboplatin: molecular mechanisms of action associated with chemoresistance.
Journal Reference Authors Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G
Title Systems biology of cisplatin resistance: past, present and future.
Journal Reference Authors Dasari S, Tchounwou PB
Title Cisplatin in cancer therapy: molecular mechanisms of action.
Journal Reference Authors Basu A, Krishnamurthy S
Title Cellular responses to Cisplatin-induced DNA damage.
Journal Reference Authors Chaudhry P, Asselin E
Title Resistance to chemotherapy and hormone therapy in endometrial cancer.
Journal Reference Authors Li X, Lin Z, Zhang B, Guo L, Liu S, Li H, Zhang J, Ye Q
Title beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
Journal Reference Authors Safaei R, Howell SB
Title Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
Journal Related KO pathway LinkDB All DBs
